J
Javier R. Lama
Researcher at Asociación Civil Impacta Salud y Educación
Publications - 141
Citations - 11117
Javier R. Lama is an academic researcher from Asociación Civil Impacta Salud y Educación. The author has contributed to research in topics: Men who have sex with men & Population. The author has an hindex of 31, co-authored 127 publications receiving 9633 citations.
Papers
More filters
Journal ArticleDOI
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant,Javier R. Lama,Peter L. Anderson,Vanessa McMahan,Albert Y. Liu,Lorena Vargas,Pedro Goicochea,Martin Casapia,Juan Vicente Guanira-Carranza,Maria Esther Ramirez-Cardich,Orlando Montoya-Herrera,Telmo Fernandez,Valdilea G. Veloso,Susan Buchbinder,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Kenneth H. Mayer,Esper G. Kallas,K. Rivet Amico,Kathleen Mulligan,Lane R. Bushman,Robert J. Hance,Carmela Ganoza,Patricia Defechereux,Brian S. Postle,Furong Wang,J. Jeff McConnell,Jia-Hua Zheng,Jeanny Lee,James F. Rooney,Howard S. Jaffe,Ana Martinez,David N. Burns,David V. Glidden +34 more
TL;DR: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects and Detectable blood levels strongly correlated with the prophylactic effect.
Journal ArticleDOI
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder,Devan V. Mehrotra,Ann Duerr,Daniel W. Fitzgerald,Robin Mogg,David Li,Peter B. Gilbert,Javier R. Lama,Michael Marmor,Carlos del Rio,M. Juliana McElrath,Danilo R. Casimiro,Keith Gottesdiener,Chodakewitz Jeffrey A,Lawrence Corey,Michael N. Robertson +15 more
TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.
Journal ArticleDOI
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Peter L. Anderson,David V. Glidden,Albert Y. Liu,Susan Buchbinder,Javier R. Lama,Juan V. Guanira,Vanessa McMahan,Lane R. Bushman,Martin Casapia,Orlando Montoya-Herrera,Valdilea G. Veloso,Kenneth H. Mayer,Kenneth H. Mayer,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Esper G. Kallas,Robert M. Grant +17 more
TL;DR: PrEP using oral FTC-TDF tablets is a robust intervention for preventing HIV acquisition among men who have sex with men, and specific drug concentrations associated with protection from HIV-1 acquisition in the iPrEx trial are estimated.
Journal ArticleDOI
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Diane V. Havlir,Michelle A. Kendall,Prudence Ive,Johnstone Kumwenda,Susan Swindells,Sarojini S. Qasba,Anne F Luetkemeyer,Evelyn Hogg,James F. Rooney,Xingye Wu,Mina C. Hosseinipour,Umesh G. Lalloo,Valdilea G. Veloso,Fatuma Some,N. Kumarasamy,Nesri Padayatchi,Breno Santos,Stewart E Reid,James Hakim,Lerato Mohapi,Peter Mugyenyi,Jorge Sanchez,Javier R. Lama,Jean W. Pape,Alejandro Sanchez,Aida Asmelash,Evans Moko,Fred Sawe,Janet Andersen,Ian Sanne +29 more
TL;DR: In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death, as compared with later ART.
Journal ArticleDOI
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)
Steven M. Goodreau,Nicole Bohme Carnegie,Eric Vittinghoff,Javier R. Lama,Jorge Sanchez,Beatriz Grinsztejn,Beryl A. Koblin,Kenneth H. Mayer,Susan Buchbinder +8 more
TL;DR: The broad balance in transmission contexts suggests that education about risk, careful assessment, pre-exposure prophylaxis, more frequent testing, earlier treatment, and risk-reduction, disclosure, and adherence counseling may all contribute substantially to reducing the HIV incidence among MSM in the US and Peru.